Why Is Macrogenics (MGNX) Stock Down 69% Today?

Macrogenics (NASDAQ:MGNX) stock is dropping hard on Friday after the after providing investors with a clinical trial update in its latest earnings report.The news that has investors spooked today has to do with fatalities during Macrogenics’ TAMARACK study. The company reported five deaths during the clinical trial.Of these five deaths, two are considered to be unconnected to the study. That includes a case of acute myocardial infarction and one cardiac arrest. The company is currently investigating the oth ...